C-peptide

C-peptide is a byproduct of insulin production — when your pancreas makes insulin, it actually produces a larger molecule called proinsulin that gets cut into two pieces: insulin and C-peptide. They’re released into the bloodstream in equal amounts, making C-peptide a direct marker of how much insulin your pancreas is producing.

Why does this matter? C-peptide has several advantages over measuring insulin directly. It’s not affected by insulin injections (injected insulin doesn’t come with C-peptide), it has a longer half-life giving more stable readings, and the liver doesn’t clear it as rapidly. This makes C-peptide the gold standard for assessing your body’s own insulin production — critical for distinguishing diabetes types and solving hypoglycemia mysteries.

For people with diabetes, C-peptide reveals how much pancreatic function remains. For those with unexplained hypoglycemia, it distinguishes between too much self-made insulin versus injected insulin. These insights directly impact treatment decisions.

Order Your Diabetes Panel

---

Key Benefits of Testing

C-peptide provides the most accurate assessment of endogenous (self-made) insulin production. This is essential when distinguishing Type 1 from Type 2 diabetes — a distinction that determines lifelong treatment strategy.

In hypoglycemia evaluation, C-peptide is invaluable. It reveals whether low blood sugar is caused by the pancreas making too much insulin (insulinoma, certain medications) or by insulin injection — information that’s impossible to obtain from insulin measurement alone in someone receiving insulin therapy.

---

What Does This Test Measure?

C-peptide measures the concentration of this peptide fragment in your blood. Since C-peptide is released in a 1:1 ratio with insulin, it directly reflects your pancreas’s insulin production.

The Proinsulin Story

Understanding C-peptide requires knowing how insulin is made:

Step 1: Pancreatic beta cells produce proinsulin — a large inactive molecule

Step 2: Proinsulin is cut into two pieces — active insulin and C-peptide (“C” stands for “connecting” peptide)

Step 3: Both insulin and C-peptide are released together into the bloodstream in equal amounts

This means C-peptide levels directly mirror insulin production by the pancreas.

Why C-Peptide Is Superior to Insulin Measurement

Not affected by exogenous insulin: Injected insulin (pharmaceutical) doesn’t contain C-peptide. So C-peptide measures only what your pancreas makes, regardless of insulin injections.

Longer half-life: C-peptide stays in blood longer than insulin (about 30 minutes vs. 5 minutes), providing more stable measurements.

Not cleared by liver: The liver removes much of the insulin on first pass, but C-peptide passes through unchanged. This makes C-peptide more accurately reflect total pancreatic output.

More consistent: Less fluctuation than insulin makes C-peptide easier to interpret.

Fasting vs. Stimulated C-Peptide

Fasting C-peptide: Baseline production when not eating. Shows minimum pancreatic function.

Stimulated C-peptide: Measured after a meal or glucose/glucagon challenge. Shows the pancreas’s ability to respond to a glucose load — its reserve capacity.

---

Why This Test Matters

Distinguishes Type 1 from Type 2 Diabetes

This is one of C-peptide’s most important uses:

Type 1 diabetes: Very low or undetectable C-peptide. The immune system has destroyed beta cells — little to no insulin production remains.

Type 2 diabetes: Normal, high, or moderately reduced C-peptide. Beta cells are present but either not responding properly (early) or becoming exhausted (late).

LADA (Latent Autoimmune Diabetes in Adults): Initially may have measurable C-peptide, but levels decline over time as autoimmune destruction progresses.

Assesses Remaining Beta Cell Function

In established diabetes, C-peptide shows how much the pancreas can still contribute. This determines:

• Whether oral medications might still work (need some insulin production)
• Whether insulin therapy is required
• Risk of diabetic ketoacidosis (higher when C-peptide is very low)
• Likelihood of hypoglycemia (more stable with some remaining production)

Solves Hypoglycemia Mysteries

When blood sugar drops dangerously low, C-peptide reveals the source:

High C-peptide during hypoglycemia: The pancreas is making too much insulin. Causes include insulinoma (tumor), sulfonylurea medications, or nesidioblastosis.

Low C-peptide with high insulin during hypoglycemia: Exogenous insulin — either therapeutic overdose or factitious (self-administered).

Low C-peptide with low insulin during hypoglycemia: Non-insulin mediated — liver disease, adrenal insufficiency, or other causes.

Guides Treatment Decisions

C-peptide helps determine the best treatment approach:

• Preserved C-peptide: May respond to oral medications, lifestyle changes
• Low C-peptide: Likely needs insulin therapy
• Undetectable C-peptide: Requires insulin; at risk for DKA

Monitors Disease Progression

Serial C-peptide measurements track beta cell decline in Type 1 diabetes and LADA, or beta cell exhaustion in Type 2 diabetes.

---

What Can Affect Your C-Peptide?

Causes of High C-Peptide

Insulin resistance:

• Type 2 diabetes (especially early)
• Prediabetes
• Obesity
• Metabolic syndrome
• PCOS

Insulinoma:

• Insulin-producing pancreatic tumor
• Causes hypoglycemia with inappropriately high C-peptide

Sulfonylurea medications:

• Stimulate insulin (and C-peptide) release
• Can cause hypoglycemia with high C-peptide

Kidney disease:

• Kidneys clear C-peptide; impaired clearance raises levels
• May overestimate beta cell function

Recent food intake:

• Eating stimulates insulin and C-peptide release

Causes of Low C-Peptide

Type 1 diabetes:

• Autoimmune beta cell destruction
• Very low or undetectable

LADA (Latent Autoimmune Diabetes in Adults):

• Slow autoimmune process
• C-peptide declines over months to years

Advanced Type 2 diabetes:

• Beta cell exhaustion after years
• C-peptide falls as disease progresses

Pancreatectomy or severe pancreatitis:

• Physical loss of beta cells

Fasting state:

• C-peptide appropriately low when not eating

Exogenous insulin (apparent low):

• Insulin therapy suppresses endogenous production
• C-peptide may be low despite high total insulin

Testing Considerations

Fasting vs. fed state: Specify which test is ordered. Fasting shows baseline; stimulated shows reserve capacity.

Kidney function: Impaired kidneys raise C-peptide independent of production. Interpret cautiously in kidney disease.

Timing with glucose: Most informative when measured alongside glucose to assess appropriateness of insulin production.

Insulin therapy: Exogenous insulin suppresses endogenous production. Time testing appropriately or use stimulation tests.

---

When Should You Get Tested?

Newly Diagnosed Diabetes (Type Uncertain)

When diabetes is diagnosed, especially in adults where type may be unclear, C-peptide helps distinguish Type 1, Type 2, and LADA — guiding immediate and long-term treatment.

Suspected LADA

Adults diagnosed with “Type 2” who have features suggesting autoimmune diabetes (lean, rapid progression, poor response to oral medications) should have C-peptide tested. Low or declining C-peptide supports LADA diagnosis.

Hypoglycemia Evaluation

Recurrent or severe low blood sugar, especially in non-diabetics or diabetics with unexplained episodes, requires C-peptide measurement during hypoglycemia to determine the cause.

Assessing Beta Cell Reserve

In established diabetes, C-peptide shows remaining pancreatic function — helpful for predicting disease course and selecting treatment.

Before Starting Insulin

Confirming low C-peptide supports the decision to start insulin therapy, especially when oral medications have failed.

Monitoring Type 1 Diabetes Research

In clinical trials and newly diagnosed Type 1 diabetes, C-peptide tracks beta cell preservation — a key outcome measure.

Order Your Test

---

Understanding Your Results

C-peptide interpretation depends on the clinical context, particularly glucose level at time of testing:

Fasting C-Peptide Patterns

Normal C-peptide with normal glucose: Normal beta cell function. Insulin production appropriate for glucose level.

High C-peptide with normal or high glucose: Insulin resistance. The pancreas is producing plenty of insulin, but cells aren’t responding. Seen in Type 2 diabetes, prediabetes, obesity.

Low C-peptide with high glucose: Insulin deficiency. The pancreas can’t produce enough insulin. Seen in Type 1 diabetes, LADA, advanced Type 2 diabetes.

High C-peptide with low glucose: Inappropriate insulin production causing hypoglycemia. Suggests insulinoma or sulfonylurea effect.

Low C-peptide with low glucose and high insulin: Exogenous insulin causing hypoglycemia (the insulin is from injection, not pancreas).

Diabetes Type Differentiation

Type 1 diabetes: Very low or undetectable C-peptide, often less than detectable limits. Requires insulin.

Type 2 diabetes: Normal to high C-peptide early; may decline over years. Often responds to oral medications initially.

LADA: Initially may have low-normal C-peptide that progressively declines. Often positive for diabetes autoantibodies.

Stimulated C-Peptide

After a meal or glucagon injection, C-peptide should rise. The degree of rise shows beta cell reserve:

• Good response: Substantial beta cell function remains
• Poor or absent response: Minimal beta cell function — likely needs insulin

---

What to Do About Abnormal Results

For Low C-Peptide (Insulin Deficiency)

Confirm diabetes type:

• Test diabetes autoantibodies (GAD65, IA-2, ZnT8, ICA) if not already done
• Positive antibodies + low C-peptide = Type 1 or LADA

Start appropriate treatment:

• Type 1 diabetes: Insulin therapy essential
• LADA: May need insulin sooner than typical Type 2; oral agents may have limited duration
• Advanced Type 2: Insulin often required when C-peptide is very low

Monitor for complications:

• Low C-peptide increases DKA risk
• More variable glucose control expected

For High C-Peptide (Insulin Resistance)

Address insulin resistance:

• Weight loss if overweight
• Exercise — improves insulin sensitivity
• Dietary modification — reduce refined carbohydrates
• Metformin if indicated

Screen for complications:

• Metabolic syndrome components
• Fatty liver
• Cardiovascular risk factors

For Hypoglycemia with High C-Peptide

Evaluate for insulinoma:

• Imaging studies (CT, MRI, endoscopic ultrasound)
• Surgical removal is often curative

Review medications:

• Sulfonylureas cause high C-peptide with hypoglycemia
• Adjust or discontinue offending medications

---

Related Health Conditions

Type 1 Diabetes

Autoimmune Beta Cell Loss: The immune system destroys insulin-producing cells. C-peptide is very low or undetectable. Lifelong insulin therapy required.

Type 2 Diabetes

Insulin Resistance with Variable Production: C-peptide is often normal or high early (resistance), declining over years (exhaustion). Treatment evolves from lifestyle to oral medications to potentially insulin.

LADA (Latent Autoimmune Diabetes in Adults)

Slow-Onset Type 1: Often misdiagnosed as Type 2 initially. C-peptide may be low-normal at diagnosis but declines over months to years. Autoantibodies are positive. May need insulin sooner than typical Type 2.

Insulinoma

Insulin-Producing Tumor: Rare pancreatic tumor causing hypoglycemia. C-peptide and insulin are both high during hypoglycemic episodes — the key diagnostic finding. Usually curable with surgery.

Factitious Hypoglycemia

Self-Administered Insulin: Hypoglycemia with high insulin but suppressed C-peptide indicates exogenous insulin. This pattern distinguishes insulin injection from insulinoma.

---

Why Regular Testing Matters

For those with diabetes, C-peptide tracks remaining beta cell function over time. In Type 1 and LADA, monitoring decline helps predict insulin needs. In Type 2, falling C-peptide signals transition from oral medications to insulin therapy.

A single C-peptide test can provide years of clarity about diabetes type and appropriate management.

---

Related Biomarkers Often Tested Together

Glucose — Essential context for C-peptide interpretation. The glucose-C-peptide relationship reveals the problem.

Insulin — Complementary to C-peptide. Together they distinguish endogenous from exogenous insulin.

HbA1c — Long-term glucose control. Part of complete diabetes assessment.

GAD65 Antibodies — Marker of autoimmune diabetes. Positive supports Type 1 or LADA diagnosis.

IA-2 Antibodies — Another autoimmune marker for diabetes classification.

Note: Information provided in this article is for educational purposes and doesn’t replace personalized medical advice.